AbbVie turns to newer immunology drugs as blockbuster Humira faces lower-cost competitionMarket Watch • 07/25/23
Analysis: Launch of arthritis drug biosimilars ramps up US pressure on pricing 'middlemen'Reuters • 07/25/23
AbbVie Advances Immunology Pipeline with First Patient Dosed in Global Phase 3 Trial of Upadacitinib (RINVOQ®) in Hidradenitis SuppurativaPRNewsWire • 07/24/23
AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)PRNewsWire • 07/21/23
Drugmakers' deal making will plow ahead despite antitrust scrutiny, analysts sayMarket Watch • 07/12/23